BACKGROUND: Previous studies reported that early progression of disease (POD) after initial therapy predicted poor overall survival (OS) in patients with follicular lymphoma (FL). Here, we investigated whether pre-treatment imaging modality had an impact on prognostic significance of POD. METHODS: In this retrospective study, we identified 1088 patients with grade I-IIIA FL; of whom, 238 patients with stage II-IV disease were initially treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP), and 346 patients were treated with rituximab-based chemotherapy. Patients (N = 484) from the FOLL05 study served as an independent validation cohort. We risk-stratified patients based on pre-treatment radiographic imaging (positron-emission tomography [PET] versus computed tomography [CT]) and early POD status using event-defining and landmark analyses. A competing risk analysis evaluated the association between early POD and histologic transformation. RESULTS: In the discovery cohort, patients with POD within 24 months (PFS24) of initiating R-CHOP therapy had a 5-year OS of 57.6% for CT-staged patients compared with 70.6% for PET-staged patients. In the validation cohort, the 5-year OS for patients with early POD was 53.9% and 100% in CT- and PET-staged patients, respectively. The risk of histologic transformation in patients whose disease progressed within one year of initiating therapy was higher in CT-staged patients than in PET-staged patients (16.7% versus 6.3%, respectively), which was associated with a 9.7-fold higher risk of death. CONCLUSION: In FL, pre-treatment PET staging reduced the prognostic impact of early POD compared with CT staging. Patients with early POD and no histologic transformation have an extended OS with standard therapy.
BACKGROUND: Previous studies reported that early progression of disease (POD) after initial therapy predicted poor overall survival (OS) in patients with follicular lymphoma (FL). Here, we investigated whether pre-treatment imaging modality had an impact on prognostic significance of POD. METHODS: In this retrospective study, we identified 1088 patients with grade I-IIIA FL; of whom, 238 patients with stage II-IV disease were initially treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP), and 346 patients were treated with rituximab-based chemotherapy. Patients (N = 484) from the FOLL05 study served as an independent validation cohort. We risk-stratified patients based on pre-treatment radiographic imaging (positron-emission tomography [PET] versus computed tomography [CT]) and early POD status using event-defining and landmark analyses. A competing risk analysis evaluated the association between early POD and histologic transformation. RESULTS: In the discovery cohort, patients with POD within 24 months (PFS24) of initiating R-CHOP therapy had a 5-year OS of 57.6% for CT-staged patients compared with 70.6% for PET-staged patients. In the validation cohort, the 5-year OS for patients with early POD was 53.9% and 100% in CT- and PET-staged patients, respectively. The risk of histologic transformation in patients whose disease progressed within one year of initiating therapy was higher in CT-staged patients than in PET-staged patients (16.7% versus 6.3%, respectively), which was associated with a 9.7-fold higher risk of death. CONCLUSION: In FL, pre-treatment PET staging reduced the prognostic impact of early POD compared with CT staging. Patients with early POD and no histologic transformation have an extended OS with standard therapy.
Authors: Ciara L Freeman; Robert Kridel; Alden A Moccia; Kerry J Savage; Diego R Villa; David W Scott; Alina S Gerrie; David Ferguson; Fergus Cafferty; Graham W Slack; Pedro Farinha; Brian Skinnider; Joseph M Connors; Laurie H Sehn Journal: Blood Date: 2019-07-12 Impact factor: 22.113
Authors: Carla Casulo; Michelle Byrtek; Keith L Dawson; Xiaolei Zhou; Charles M Farber; Christopher R Flowers; John D Hainsworth; Matthew J Maurer; James R Cerhan; Brian K Link; Andrew D Zelenetz; Jonathan W Friedberg Journal: J Clin Oncol Date: 2015-06-29 Impact factor: 44.544
Authors: Laurie H Sehn; Neil Chua; Jiri Mayer; Gregg Dueck; Marek Trněný; Kamal Bouabdallah; Nathan Fowler; Vincent Delwail; Oliver Press; Gilles Salles; John Gribben; Anne Lennard; Pieternella J Lugtenburg; Natalie Dimier; Elisabeth Wassner-Fritsch; Günter Fingerle-Rowson; Bruce D Cheson Journal: Lancet Oncol Date: 2016-06-23 Impact factor: 41.316
Authors: S Wöhrer; U Jaeger; K Kletter; A Becherer; A Hauswirth; K Turetschek; M Raderer; M Hoffmann Journal: Ann Oncol Date: 2006-02-23 Impact factor: 32.976
Authors: John P Leonard; Sin-Ho Jung; Jeffrey Johnson; Brandelyn N Pitcher; Nancy L Bartlett; Kristie A Blum; Myron Czuczman; Jeffrey K Giguere; Bruce D Cheson Journal: J Clin Oncol Date: 2015-08-24 Impact factor: 44.544
Authors: C Y Cheah; D Chihara; M Ahmed; R E Davis; L J Nastoupil; K Phansalkar; F B Hagemeister; L E Fayad; J R Westin; Y Oki; M A Fanale; J E Romaguera; M L Wang; H Lee; F Turturro; F Samaniego; M A Rodriguez; S S Neelapu; N H Fowler Journal: Ann Oncol Date: 2016-01-22 Impact factor: 32.976
Authors: Frederick Lansigan; Ian Barak; Brandelyn Pitcher; Sin-Ho Jung; Bruce D Cheson; Myron Czuczman; Peter Martin; Eric Hsi; Heiko Schöder; Scott Smith; Nancy L Bartlett; John P Leonard; Kristie A Blum Journal: Cancer Med Date: 2018-12-21 Impact factor: 4.452
Authors: Vít Procházka; David Belada; Andrea Janíková; Kateřina Benešová; Heidi Mociková; Juraj Ďuraš; Jan Pirnos; Kateřina Kopečková; Vít Campr; Tomáš Fürst; Robert Pytlík; Alice Sýkorová; Jozef Michalka; Jitka Dlouhá; Tomáš Papajík; Marek Trněný Journal: EJHaem Date: 2020-07-31
Authors: Melissa Lumish; Lorenzo Falchi; Brandon S Imber; Michael Scordo; Gottfried von Keudell; Erel Joffe Journal: J Hematol Oncol Date: 2021-01-06 Impact factor: 17.388
Authors: Fushen Sha; Michelle Okwali; Anna Alperovich; Philip C Caron; Lorenzo Falchi; Audrey Hamilton; Paul A Hamlin; Steven M Horwitz; Erel Joffe; Niloufer Khan; Anita Kumar; Matthew J Matasar; Alison J Moskowitz; Ariela Noy; Colette Owens; Lia M Palomba; Ildefonso Rodriguez-Rivera; David Straus; Gottfried von Keudell; Andrew D Zelenetz; Joachim Yahalom; Ahmet Dogan; Heiko Schöder; Venkatraman E Seshan; Gilles Salles; Anas Younes; Connie L Batlevi Journal: Blood Cancer J Date: 2022-02-10 Impact factor: 11.037